Neurologists get their first formal guidance on consumer wearables

American Academy of Neurology

Your smartwatch can detect atrial fibrillation. Your fitness tracker can estimate sleep stages. Your headache app can log triggers and patterns. But should your neurologist care about any of this data?

The American Academy of Neurology thinks so, with caveats. In a new Emerging Issues in Neurology article published March 11, 2026, in Neurology, the AAN provides its first formal guidance on consumer wearable devices and digital health apps for neurological care. The guidance focuses specifically on non-FDA-cleared technology, the kind of devices millions of people already own and use daily.

Seizure tracking and headache biofeedback

For epilepsy, the guidance notes that wearable devices and digital apps can help detect seizures, understand their impact, and identify triggers. Preliminary studies have shown that pairing a fitness tracker with an electronic seizure diary improves forecasting accuracy. The authors suggest that with further development, wearable technology could enable more personalized epilepsy treatment.

For headache management, some devices provide biofeedback using sensors that monitor muscle tension, heart rate, and skin temperature to help patients manage stress responses that can trigger headaches. Wearables using actigraphy, which tracks rest and activity cycles, have revealed patterns like increased sleep and reduced activity during headache episodes. But challenges persist with data completeness and whether patients use the devices consistently enough to produce reliable information.

Heart rhythm screening and sleep monitoring

Consumer smartwatches can now screen for atrial fibrillation, a heart rhythm abnormality linked to increased stroke risk. The guidance recommends that neurologists treat these as screening tools, not diagnostic instruments. Additional medical testing is usually needed to confirm findings. And there is a real concern: patients waiting for confirmatory results may experience significant anxiety from wearable alerts. Physicians should consider whether to initiate preventive treatment while confirmation is pending.

Sleep tracking has advanced rapidly, with wristbands, rings, and headbands now capable of estimating sleep duration and stages. The technology offers advantages over traditional sleep studies by being more affordable and allowing monitoring in a patient's normal home environment. But physicians may not have full access to the raw data, and the accuracy of consumer-grade sleep staging remains inconsistent compared to clinical polysomnography.

The gap between data and clinical decisions

Lead author Sarah M. Benish of the University of Minnesota framed the central challenge clearly: wearable technology generates a flood of health data, but neurologists need guidance on how to interpret it, when to act on it, and when to set it aside.

The guidance identifies several persistent concerns. Accuracy varies significantly between devices and between individuals. Readings can be falsely alarming, prompting unnecessary emergency visits, or falsely reassuring, giving patients a false sense of security about conditions that warrant medical attention. Both scenarios carry real clinical consequences.

Anxiety is an underappreciated side effect. Continuous health monitoring can make some patients hypervigilant about every data point, creating psychological burden rather than reducing it. Neurologists are advised to discuss this possibility proactively.

Data privacy remains a concern. Consumer devices collect granular health data that may be shared with third parties under terms of service that patients rarely read. The guidance does not resolve this issue but flags it as something physicians should be aware of when recommending device use.

Equity and access

Consumer wearables are not cheap. The guidance acknowledges that cost-related disparities could widen existing gaps in neurological care if wearable-informed treatment becomes standard. Patients who cannot afford the devices, or who lack the digital literacy to use them effectively, could find themselves at a disadvantage.

Not a replacement, not yet validated

The guidance explicitly does not endorse any specific device or app. It does not treat consumer wearables as validated medical instruments. Instead, it positions them as potentially useful adjuncts to clinical care, sources of supplementary data that may inform but should not dictate treatment decisions.

The evidence base remains limited. Most studies of wearables in neurological care are small, short-term, and focused on feasibility rather than clinical outcomes. Whether wearable data actually improves patient outcomes, reduces hospitalizations, or enables earlier intervention is largely unproven.

What the guidance does accomplish is legitimizing the conversation. Patients are already wearing these devices and sharing data with their doctors. Neurologists now have a framework, however provisional, for engaging with that information rather than ignoring it.